Relmada Therapeutics, Inc. (NasdaqCM: RLMD)
Health Care · Pharmaceuticals · US
$3.45
+1.62% today · +66.2% 1Y
Relmada Therapeutics, Inc. (NasdaqCM: RLMD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $361.61M and employs 17 people.
Over the last twelve months the share price has gained 66.2%, trading between 1.80 and 8.00.
Tweenvest scores Relmada Therapeutics, Inc. across four factors: quality 35/100, value 70/100. Its strongest factor is value.
RLMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $361.61M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.85
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- $8.00
- 52-week low
- $1.80
- Avg volume (3M)
- —
- Shares outstanding
- 106.67M
- Employees
- 17
- Next earnings
- —
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
- ISIN
- US75955J4022
- Founded
- 2004
- Listed since
- Jun 20, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Taho Pharmaceuticals Ltd.TPEX: 6467 | $368.78M | NT$225.00 | -2.60% |
| Egyptian International Pharmaceutical Industries CompanyCASE: PHAR | $367.68M | EGP114.10 | -1.47% |
| GlaxoSmithKline Pakistan LimitedKASE: GLAXO | $364.11M | PKRs316.60 | +1.20% |
| Zhejiang Xinguang Pharmaceutical Co., Ltd.SZSE: 300519 | $362.13M | CN¥15.16 | +2.29% |
| ASKA Pharmaceutical Holdings Co.,Ltd.TSE: 4886 | $359.39M | ¥2,004.00 | -1.28% |
| Suzhou Fushilai Pharmaceutical Co., Ltd.SZSE: 301258 | $357.63M | CN¥27.04 | -1.31% |
| Turn Therapeutics Inc.NasdaqGM: TTRX | $357.46M | $11.48 | -4.33% |
| ShanXi C&Y Pharmaceutical Group Co.,LTD.SZSE: 300254 | $356.35M | CN¥9.28 | +0.98% |
Figures last refreshed Oct 11, 2026.